ProShare Advisors LLC Sells 5,272 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

ProShare Advisors LLC lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 22.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,963 shares of the company’s stock after selling 5,272 shares during the period. ProShare Advisors LLC’s holdings in Intellia Therapeutics were worth $402,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of NTLA. Vanguard Group Inc. raised its position in shares of Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after buying an additional 746,263 shares in the last quarter. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 5.5% during the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock worth $259,514,000 after acquiring an additional 606,507 shares during the last quarter. Norges Bank purchased a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $16,348,000. Federated Hermes Inc. lifted its stake in shares of Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Intellia Therapeutics in the 4th quarter worth approximately $9,086,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. decreased their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. Finally, Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $61.77.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $19.20 on Wednesday. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -3.58 and a beta of 1.77. The firm’s 50-day moving average is $22.64 and its two-hundred day moving average is $23.74. Intellia Therapeutics, Inc. has a 1 year low of $18.96 and a 1 year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The business’s quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.40) EPS. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.